Details
Description
Inclusion Criteria
Exclusion Criteria
Details
Title A randomized phase II study with a phase I lead-in to assess the antitumor efficacy of the MEK inhibitor Trametinib alone or in combination with GSK2141795, an AKT inhibitor in patients with recurrent or persistent endometrial cancer.
IRB GOG0229O
CC 13-1497
Hospital Fairview, Hillcrest, Main Campus
Disease Gynecologic
Drug GSK2141795, Trametinib
